ARK Genomic Revolution ETF vs Carvana Co — how do they compare? ARK Genomic Revolution ETF trades at $44.5, while Carvana Co trades at $71.14 (market cap $79.17B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.
| ARKG | CVNA | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $44.55 | $95.69 |
52-Week Low | $24.02 | $56.27 |
Market Cap | — | $79.17B |
Enterprise Value | — | $81.65B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Carvana (CVNA) trades at $70.83, down 4.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported record Q2 2026 results with revenue up 52% year-over-year to $7.38 billion and net income of $513 million, though shares fell due to disappointing full-year EBITDA guidance. Strong cash flow generation continues with 2025 operating cash flow of $1.04 billion.
Outlook remains positive with analyst consensus price target of $87.18 implying 23% upside, but execution risks and premium valuation (P/E 38.1) temper enthusiasm. Key risks include profit margin compression and high debt levels despite improving leverage ratios. The stock faces near-term pressure from guidance concerns but maintains long-term growth potential.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →